Altimmune completes enrollment in Phase 2 trial of HepTcell

Altimmun announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B. With the achievement of this milestone, data readout is planned for the first quarter of 2024. The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen. "We are pleased to have achieved this milestone in the HepTcell Phase 2 trial and look forward to the data readout in Q1 2024," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "In addition, we look forward to initiating our Phase 2b biopsy non-alcoholic steatohepatitis (NASH) trial in mid-2023 and announcing topline data from our 48-week MOMENTUM obesity trial in the fourth quarter of 2023."